NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalPRNewsWire • 12/11/23
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell TherapiesPRNewsWire • 12/06/23
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementPRNewsWire • 11/28/23
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending MergerPRNewsWire • 11/10/23
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase WarrantsPRNewsWire • 11/09/23
INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVOBusiness Wire • 10/25/23
Shareholder Alert: Ademi LLP investigates whether INVO Bioscience, Inc. has obtained a Fair Price in its transaction with NAYA BiosciencesPRNewsWire • 10/23/23
INVO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of INVO Bioscience, Inc. Is Fair to ShareholdersBusiness Wire • 10/23/23
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science CompanyPRNewsWire • 10/23/23
INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ETPRNewsWire • 09/28/23
INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder ValuePRNewsWire • 08/03/23